Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Protein Analysis Reagents
  4. Bioactive Small Molecules
  5. 706450

Tocris Bioscience™ Ruxolitinib
GREENER_CHOICE

Catalog No. 706450
Change view
Click to view available options
Quantity:
50 mg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
70-645-0 50 mg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
This item is not returnable. View return policy
Catalog No. 70-645-0 Supplier Tocris Bioscience™ Supplier No. 7064/50
Only null left
Add to Cart
Add to Cart
This item is not returnable. View return policy

Description

Potent and selective JAK1/JAK2 inhibitor; orally bioavailable

Ruxolitinib is a potent and selective JAK1/2 inhibitor (IC50 values are 3.3 and 2.8 nM, respectively). Exhibits selectivity for JAK1/2 over Tyk2 and JAK3 (∼6-fold and >130-fold, respectively). Exhibits no significant inhibition against a commercial panel of 26 additional kinases. Inhibits JAK2V617F-mediated signaling and proliferation in Ba/F3 cells and HEL cells. Increases survival rates in a JAK2V617F-driven mouse model. Identified as targeting human host proteins that interact with SARS-CoV-2. Orally bioavailable.

Phosphate salt (Cat. No. 7048) also available.

Specifications

Chemical Name or Material (3 R)-3-Cyclopentyl-3-[4-(7 H-pyrrolo[2,3-d]pyrimidin-4-yl)-1 H-pyrazol-1-yl]propanenitrile
CAS 941678-49-5
Quantity 50 mg
Target JAK Kinase Inhibitors
Molecular Formula C17H18N6
Formula Weight 2323
Purity 98%
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.